Venturi Wealth Management LLC Sells 403 Shares of Thermo Fisher Scientific Inc. $TMO

Venturi Wealth Management LLC lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 27.0% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,088 shares of the medical research company’s stock after selling 403 shares during the quarter. Venturi Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $441,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. CBIZ Investment Advisory Services LLC grew its position in Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock valued at $28,000 after buying an additional 33 shares during the period. Anderson Financial Strategies LLC bought a new position in Thermo Fisher Scientific during the first quarter worth about $30,000. Keystone Global Partners LLC bought a new position in Thermo Fisher Scientific during the first quarter worth about $31,000. IMA Advisory Services Inc. bought a new position in Thermo Fisher Scientific during the first quarter worth about $35,000. Finally, Smallwood Wealth Investment Management LLC bought a new position in Thermo Fisher Scientific during the first quarter worth about $37,000. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Down 0.2%

Shares of TMO opened at $534.92 on Friday. The firm’s 50 day simple moving average is $487.44 and its 200 day simple moving average is $448.31. The company has a market capitalization of $201.99 billion, a P/E ratio of 30.94, a P/E/G ratio of 2.91 and a beta of 0.77. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. Thermo Fisher Scientific’s quarterly revenue was up 2.9% on a year-over-year basis. During the same period last year, the firm posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares of the company’s stock, valued at approximately $57,697,567.04. This trade represents a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

TMO has been the subject of a number of research reports. UBS Group increased their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a “neutral” rating in a research report on Thursday, July 24th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Thermo Fisher Scientific in a research report on Saturday, September 27th. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 4th. Hsbc Global Res downgraded shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 24th. Finally, HSBC reissued a “hold” rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $593.43.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.